You are here: Industry Insights > Eisai

News List

Eisai submits marketing authorization application for Insomnia drug biospectrumasia
March 07, 2019
This application was based on the results of two pivotal Phase III clinical studies in patients with insomnia, SUNRISE 1 (Study 304) and SUNRISE 2 (Study 303)
Eisai seeks EMA approval for Fycompa to treat epilepsy in paediatrics pharmaceutical-technology
February 15, 2019
Eisai has submitted an application to the European Medicines Agency (EMA) seeking approval for the use of its Fycompa (perampanel) medicine to treat paediatric patients suffering with epilepsy....
Eisai and Purdue Pharma seek US approval for lemborexant to treat insomnia pharmaceutical-technology
January 17, 2019
Eisai and its partner Purdue Pharma have submitted new drug application to the US Food and Drug Administration (FDA) seeking approval for lemborexant to treat insomnia, a sleep disorder.....
NDA for Lemborexant Submitted in the United States americanpharmaceuticalreview
January 16, 2019
Eisai and Purdue Pharma announced a new drug application has been submitted to the U.S. Food and Drug Administration (FDA) for lemborexant ....
Eisai, UCL extend neuro pact, gear up for Alzheimer’s phase 1 fiercebiotech
December 28, 2018
Six years after Eisai and University College London teamed up to discover new treatments for neurological diseases, they are moving their first candidate into the clinic.....
NICE recommends Lenvima for advanced liver cancer pharmatimes
December 24, 2018
The National Institute for Health and Care excellence (NICE) has recommended Eisai and MSD’s Lenvima (lenvatinib), a potentially life-extending treatment for advanced hepatocellular carcinoma (HCC) in adults
GARDP, Eisai and Takeda join forces to identify new antibiotics pharmaceutical-technology
December 13, 2018
The Global Antibiotic Research and Development Partnership (GARDP) in Switzerland has partnered with Eisai and Takeda Pharmaceutical in a bid to discover new antibiotics.....
Eisai, UCL commence phase I clinical studies for anti-tau monoclonal antibody expressbpd
December 10, 2018
Eisai, UCL commence phase I clinical studies for anti-tau monoclonal antibody
Eisai and UCL deepen drug discovery alliance pharmaceutical-technology
December 10, 2018
Japanese pharmaceutical company Eisai has expanded its drug discovery collaboration with University College London (UCL) in the UK for additional five years to 2023......
Halaven maker Eisai launches metastatic breast cancer story-sharing campaign fiercepharma
December 10, 2018
Metastatic breast cancer (MBC) can make patients feel isolated, and that’s the feeling Eisai is working to combat with its latest awareness campaign.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page